Emerging Therapy Solutions has filed a notice of an exempt offering of securities to raise $5 Million in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Emerging Therapy Solutions is raising up to $5,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Dave Mclean played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Emerging Therapy Solutions
Emerging Therapy Solutions (ETS) was founded in 2018 by industry veterans of managed care solutions, healthcare biotech and transplant to help healthcare payers manage the risks associated with high-cost therapies for rare and complex conditions. ETS acquired LifeTrac in 2020, bringing over 30 years of experience in bone marrow and solid organ transplants, plus provider relationships and agreements, to complement Emerging Therapy Solutions expertise in cell and gene therapies. The integrated business offers payers a comprehensive suite of services for solid organ and bone marrow transplants, cell and gene therapies, and other highly specialized therapies.
To learn more about Emerging Therapy Solutions, visit http://emergingtherapies.com/
Contact:
Dave Mclean, Chief Executive Officer
612-371-3507
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.